US 12,303,530 B2
Combination therapy of cycloserine and lithium for the treatment of depression
Sukchan Lee, Yongin-si (KR); Yong Ha Chi, Seogwipo-si (KR); Dong Cheol Jang, Wonju-si (KR); and Gibeom Kwon, Suwon-si (KR)
Assigned to NEURORIVE INC, Seoul (KR)
Appl. No. 17/771,648
Filed by NEURORIVE INC, Seoul (KR)
PCT Filed Nov. 27, 2020, PCT No. PCT/KR2020/017101
§ 371(c)(1), (2) Date Apr. 25, 2022,
PCT Pub. No. WO2021/107690, PCT Pub. Date Jun. 3, 2021.
Claims priority of application No. 10-2019-0154218 (KR), filed on Nov. 27, 2019.
Prior Publication US 2022/0387481 A1, Dec. 8, 2022
Int. Cl. A61K 31/42 (2006.01); A61K 33/00 (2006.01); A61P 25/24 (2006.01)
CPC A61K 33/00 (2013.01) [A61K 31/42 (2013.01); A61P 25/24 (2018.01)] 6 Claims
OG exemplary drawing
 
1. A method for preventing or treating depression comprising administering to a subject in need there of a therapeutically effective amount of (i) cycloserine or a pharmaceutically acceptable salt thereof; and (ii) lithium or a pharmaceutically acceptable salt thereof,
wherein a weight ratio of (i) the cycloserine or the pharmaceutically acceptable salt thereof; and (ii) the lithium or the pharmaceutically acceptable salt thereof is 10:5 to 10:1.